Kinnate Biopharma (NASDAQ:KNTE – Get Rating) had its price objective decreased by Stifel Nicolaus from $11.00 to $8.00 in a research note issued to investors on Thursday, Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.
Separately, Wedbush decreased their price target on shares of Kinnate Biopharma to $29.00 in a research report on Wednesday, November 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $25.00.
Kinnate Biopharma Trading Down 0.7 %
NASDAQ:KNTE opened at $5.42 on Thursday. Kinnate Biopharma has a 1 year low of $3.30 and a 1 year high of $15.86. The firm’s fifty day simple moving average is $6.17 and its 200 day simple moving average is $8.14.
Hedge Funds Weigh In On Kinnate Biopharma
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. bought a new position in shares of Kinnate Biopharma during the 4th quarter worth about $81,000. Jane Street Group LLC bought a new position in shares of Kinnate Biopharma during the 4th quarter worth about $77,000. SVB Financial Group bought a new position in shares of Kinnate Biopharma during the 4th quarter worth about $143,000. Squarepoint Ops LLC bought a new position in shares of Kinnate Biopharma during the 4th quarter worth about $153,000. Finally, Marshall Wace LLP lifted its holdings in shares of Kinnate Biopharma by 30.5% during the 4th quarter. Marshall Wace LLP now owns 14,944 shares of the company’s stock worth $91,000 after acquiring an additional 3,492 shares during the period. 98.68% of the stock is owned by institutional investors.
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.